Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Activation of Integrins01:15

Activation of Integrins

3.3K
Integrins bind ligands and transmit information from outside the cell to inside or vice-versa through an "outside-in signaling" or "inside-out signaling."
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding...
3.3K
Integrins01:10

Integrins

3.8K
Animal and protozoan cells do not have cell walls to help maintain shape and provide structural stability. Instead, these eukaryotic cells secrete a sticky mass of carbohydrates and proteins into the spaces between adjacent cells. This network of proteins and molecules is called an extracellular matrix or ECM.
Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...
3.8K
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

2.5K
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
2.5K
The Two-State Receptor Model01:29

The Two-State Receptor Model

1.9K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
1.9K
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

2.3K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.3K
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

2.7K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
2.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chimeric peptide-based radiopharmaceuticals for glioblastoma imaging and therapy by targeting mHsp70 and enhancing BBB penetration.

Chemical science·2026
Same author

From Nodal Metastasis to Oncologic Recurrence in Tongue and Oral Floor Squamous Cell Carcinoma: Distinct Failure Patterns and Clinicopathological Risk Profiles.

Head & neck·2026
Same author

Contrast enhanced CT and MRI interchangeably reflect tumor characteristics in murine pancreatic cancer.

Scientific reports·2026
Same author

The Role of Preoperative Lower Extremity CT Angiography in Mandible Reconstruction: A Retrospective Cohort Analysis.

Journal of reconstructive microsurgery·2026
Same author

Linker Optimization in Lu-177 Labeled αvβ6-Integrin Binding Peptide Trimers for Targeted Radionuclide Therapy of Cancer.

Molecular pharmaceutics·2026
Same author

Correlation of preoperative radiological lymph node assessment with pathological nodal and tumor findings in tongue and oral floor squamous cell carcinoma.

Journal of cancer research and clinical oncology·2026

Related Experiment Video

Updated: May 29, 2025

Static Adhesion Assay for the Study of Integrin Activation in T Lymphocytes
09:14

Static Adhesion Assay for the Study of Integrin Activation in T Lymphocytes

Published on: June 13, 2014

16.0K

Switching Roles─Exploring Concentration-Dependent Agonistic versus Antagonistic Behavior of Integrin Ligands.

Beatrice Stefanie Ludwig1,2, Nils Krautkremer3, Stefano Tomassi4

  • 1Department of Nuclear Medicine, School of Medicine & Health, Klinikum rechts der Isar, TUM University Hospital, Technical University of Munich, Ismaninger Strasse 22, Munich 81675, Germany.

Journal of Medicinal Chemistry
|February 5, 2025
PubMed
Summary

Cancer integrin ligands show complex concentration-dependent effects. Some ligands, like cilengitide, can unexpectedly promote angiogenesis at low doses, while others exhibit dual agonistic and antagonistic functions, necessitating careful evaluation for therapeutic use.

More Related Videos

Author Spotlight: Development of a Method for Identifying Small Molecular Antagonists of β2 Integrin Activation
04:15

Author Spotlight: Development of a Method for Identifying Small Molecular Antagonists of β2 Integrin Activation

Published on: February 2, 2024

1.7K
Ligand Nano-cluster Arrays in a Supported Lipid Bilayer
10:34

Ligand Nano-cluster Arrays in a Supported Lipid Bilayer

Published on: April 23, 2017

6.9K

Related Experiment Videos

Last Updated: May 29, 2025

Static Adhesion Assay for the Study of Integrin Activation in T Lymphocytes
09:14

Static Adhesion Assay for the Study of Integrin Activation in T Lymphocytes

Published on: June 13, 2014

16.0K
Author Spotlight: Development of a Method for Identifying Small Molecular Antagonists of β2 Integrin Activation
04:15

Author Spotlight: Development of a Method for Identifying Small Molecular Antagonists of β2 Integrin Activation

Published on: February 2, 2024

1.7K
Ligand Nano-cluster Arrays in a Supported Lipid Bilayer
10:34

Ligand Nano-cluster Arrays in a Supported Lipid Bilayer

Published on: April 23, 2017

6.9K

Area of Science:

  • Integrin biology
  • Cancer therapeutics
  • Molecular signaling

Background:

  • Integrins are key targets in cancer therapy, leading to the development of specific inhibitory ligands.
  • The clinical failure of cilengitide due to promoting angiogenesis at low concentrations prompted scrutiny of pure ligand antagonism.

Purpose of the Study:

  • To evaluate the concentration-dependent functional effects of integrin ligands (αvβ3, αvβ6, α5β1) on cancer cells.
  • To investigate the signaling pathways (FAK, ERK) and cell migration responses to these ligands.

Main Methods:

  • Assessed integrin ligands (L1, L2, L3, L5) for their effects on specific integrin subtypes (αvβ3, αvβ6, α5β1) overexpressing cancer cells.
  • Monitored phosphorylation of focal adhesion kinase (p-FAK) and p44/42 extracellular signal-regulated kinase (p-p44/42 ERK1/2).
  • Evaluated ligand-induced changes in cell migration at varying concentrations.

Main Results:

  • Cilengitide (L2) and L1 induced transient signaling changes at low concentrations and inhibited cell migration at high concentrations, but accelerated it at low concentrations.
  • L5 (α5β1 ligand) demonstrated bell-shaped FAK activation and blocked migration at high concentrations in specific cells.
  • L3 (αvβ6 ligand) showed transient FAK activation but no significant impact on cell motility.

Conclusions:

  • Integrin ligand activity is concentration-dependent and can exhibit complex functional switches, including both antagonistic and agonistic effects.
  • The findings highlight the critical need for thorough evaluation of ligand actions to optimize their medical application in cancer therapy.
  • Understanding these nuanced effects is crucial for developing safe and effective integrin-targeted cancer treatments.